About Antheia
Antheia is a company based in Palo Alto (United States) founded in 2013 by Christina Smolke and Kristy Hawkins. Antheia has raised $176.37 million across 13 funding rounds from investors including SVB, HHS and Oxford Finance. The company has 50 employees as of December 31, 2022. Antheia offers products and services including Biosynthetic APIs and Key Starting Materials (KSMs). Antheia operates in a competitive market with competitors including Amyris, Syngenta, Avidity Biosciences, AskBio and Univercells, among others.
- Headquarter Palo Alto, United States
- Employees 50 as on 31 Dec, 2022
- Founders Christina Smolke, Kristy Hawkins
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Antheia, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$176.37 M (USD)
in 13 rounds
-
Latest Funding Round
$24 M (USD), Series C
Jan 27, 2026
-
Investors
SVB
& 14 more
-
Employee Count
50
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Antheia
Antheia offers a comprehensive portfolio of products and services, including Biosynthetic APIs and Key Starting Materials (KSMs).
Produces active ingredients via synthetic biology for drug manufacturing
Engineers yeast to create essential precursors for pharmaceuticals efficiently
People of Antheia
Unlock access to complete
Funding Insights of Antheia
Antheia has successfully raised a total of $176.37M across 13 strategic funding rounds. The most recent funding activity was a Series C round of $24 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Antheia
Antheia has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, HHS and Oxford Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm
|
Locked | Locked | Locked | |
|
Echo Investment Capital is engaged in multi-strategy investment management.
|
Locked | Locked | Locked | |
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Antheia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Antheia
Investment portfolio details for Antheia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Antheia
Detailed financials for Antheia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Antheia Comparisons
Peer comparison for Antheia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Antheia
Antheia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Syngenta, Avidity Biosciences, AskBio and Univercells, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Crop protection solutions and hybrid seeds are provided for farming.
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
Detailed competitors of Antheia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Antheia
Complete news archive for Antheia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Antheia
Antheia was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Antheia is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Christina Smolke is the current CEO of Antheia. They have also founded this company.
Antheia is a funded company, having raised a total of $176.37M across 13 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Antheia is 50.
Antheia was founded in 2013 in Palo Alto, United States, within the synthetic biology sector. Medicines are developed through the integration of synthetic biology, informatics, and fermentation technologies. Yeast cells are engineered to yield plant-based medicinal products. Operations center on creating natural compounds for therapeutic applications, with a focus on scalable production methods.
Antheia's top competitors include Syngenta, Sutro Biopharma and Avidity Biosciences.
Antheia offers Biosynthetic APIs and Key Starting Materials (KSMs).
Antheia has 15 investors. Key investors include SVB, HHS, Oxford Finance, In-Q-Tel, and Echo Investment Capital.